Collegium Pharmaceutical (COLL) Liabilities and Shareholders Equity (2014 - 2026)

Collegium Pharmaceutical's Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 1.26% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $6.5 billion (up 8.78% YoY), while the FY2025 annual figure was $1.7 billion, changed 0.41% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.7 billion, roughly flat from $1.7 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.7 billion in Q4 2024, with the low at $1.1 billion in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2022), against an average of $1.4 billion.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 92.88% in 2022, then dropped 13.22% in 2024.
• Collegium Pharmaceutical's Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then retreated by 2.63% to $1.1 billion in 2023, then jumped by 45.51% to $1.7 billion in 2024, then fell by 0.41% to $1.7 billion in 2025, then decreased by 0.29% to $1.7 billion in 2026.
• Business Quant data shows COLL's Liabilities and Shareholders Equity at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.6 billion in Q3 2025.